Iovance Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Iovance Biotherapeutics's earnings have been declining at an average annual rate of -22.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 103.1% per year.
Key information
-22.5%
Earnings growth rate
-10.8%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 103.1% |
Return on equity | -76.0% |
Net Margin | -37,345.4% |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Iovance Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -444 | 107 | 344 |
30 Sep 23 | 1 | -433 | 103 | 337 |
30 Jun 23 | 0 | -419 | 104 | 322 |
31 Mar 23 | 0 | -412 | 109 | 309 |
31 Dec 22 | 0 | -396 | 104 | 295 |
30 Sep 22 | 0 | -390 | 101 | 290 |
30 Jun 22 | 0 | -376 | 94 | 283 |
31 Mar 22 | 0 | -358 | 87 | 271 |
31 Dec 21 | 0 | -342 | 84 | 259 |
30 Sep 21 | 0 | -311 | 76 | 236 |
30 Jun 21 | 0 | -284 | 71 | 214 |
31 Mar 21 | 0 | -265 | 66 | 201 |
31 Dec 20 | 0 | -260 | 60 | 202 |
30 Sep 20 | 0 | -255 | 55 | 204 |
30 Jun 20 | 0 | -246 | 49 | 202 |
31 Mar 20 | 0 | -230 | 46 | 192 |
31 Dec 19 | 0 | -198 | 41 | 166 |
30 Sep 19 | 0 | -167 | 38 | 139 |
30 Jun 19 | 0 | -151 | 35 | 126 |
31 Mar 19 | 0 | -134 | 31 | 111 |
31 Dec 18 | 0 | -124 | 28 | 100 |
30 Sep 18 | 0 | -117 | 26 | 93 |
30 Jun 18 | 0 | -105 | 25 | 82 |
31 Mar 18 | 0 | -98 | 23 | 76 |
31 Dec 17 | 0 | -92 | 21 | 72 |
30 Sep 17 | 0 | -82 | 13 | 61 |
30 Jun 17 | 0 | -128 | 17 | 53 |
31 Mar 17 | 0 | -116 | 20 | 38 |
31 Dec 16 | 0 | -102 | 17 | 27 |
30 Sep 16 | 0 | -95 | 25 | 21 |
30 Jun 16 | 0 | -34 | 18 | 17 |
31 Mar 16 | 0 | -29 | 12 | 17 |
31 Dec 15 | 0 | -28 | 12 | 15 |
30 Sep 15 | 0 | -24 | 10 | 14 |
30 Jun 15 | 0 | -19 | 10 | 9 |
31 Mar 15 | 0 | -15 | 9 | 6 |
31 Dec 14 | 0 | -12 | 8 | 4 |
30 Sep 14 | 0 | -27 | 7 | 2 |
30 Jun 14 | 0 | -34 | 7 | 2 |
31 Mar 14 | 0 | -35 | 6 | 1 |
31 Dec 13 | 0 | -34 | 4 | 2 |
30 Sep 13 | 0 | -10 | 5 | 1 |
Quality Earnings: 0JDK is currently unprofitable.
Growing Profit Margin: 0JDK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0JDK is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare 0JDK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0JDK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0JDK has a negative Return on Equity (-75.95%), as it is currently unprofitable.